Document Detail


Human glioma U-251 cells contain type 1 plasminogen activator inhibitor in a rapidly releasable form.
MedLine Citation:
PMID:  8814293     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Because recent information suggests that the localized deposition of protease inhibitors is one mechanism by which cells regulate pericellular proteolysis during tissue invasion, the distribution of type 1 plasminogen activator inhibitor (PA1-1) associated with the invasive human glioma cell line U-251 was investigated. Direct and reverse fibrin zymography indicated the presence of urokinase-like plasminogen activator (u-PA) and PAI-1 in U-251 conditioned media and cell lysates. PA1-1 antigen was detected immunologically in cytoplasmic granules present within cellular processes of U-251 cells and these organelles could be isolated on Percoll density gradients in a high density band. In contrast, u-PA activity and another secreted protein, amyloid beta-protein precursor, were only present in the low density region of the gradients. Functional analysis of PAI-1 in the granules contained within the high density fractions revealed the presence of active PAI-1. Incubation of U-251 cells with the secretagogue, 8-bromoadenosine 3':5'-cyclic monophosphate, resulted in a 3-fold increase in the release of PAI-1 in the media conditioned by these cells. These data suggest that the human glioma cell line U-251 contains PAI-1 in a rapidly releasable form, which may provide another mechanism by which these tumors could regulate proteolytic activity in a localized manner.
Authors:
E M Salonen; L Gombau; E Engvall; R R Schleef
Related Documents :
7962113 - Human co115 colon carcinoma cells potentiate the degradation of laminin mediated by tis...
7864083 - Characterization of plasminogen system on rat yolk sac carcinoma (l2) cells.
16034823 - Rapamycin pre-treatment preserves viability, atp level and catabolic capacity during ca...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  FEBS letters     Volume:  393     ISSN:  0014-5793     ISO Abbreviation:  FEBS Lett.     Publication Date:  1996 Sep 
Date Detail:
Created Date:  1996-11-07     Completed Date:  1996-11-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0155157     Medline TA:  FEBS Lett     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  216-20     Citation Subset:  IM    
Affiliation:
Department of Vascular Biology, Scripps Research Institute, La Jolla, CA 92037, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
8-Bromo Cyclic Adenosine Monophosphate / pharmacology
Cell Fractionation
Cell Line
Centrifugation, Density Gradient
Fibrin
Fibrinolysis*
Glioma
Humans
Immunohistochemistry
Neoplasm Invasiveness
Organelles / drug effects,  metabolism,  ultrastructure
Plasminogen Activator Inhibitor 1 / isolation & purification,  metabolism*
Povidone
Silicon Dioxide
Tumor Cells, Cultured
Urokinase-Type Plasminogen Activator / isolation & purification,  metabolism*
Grant Support
ID/Acronym/Agency:
HL45954/HL/NHLBI NIH HHS; HL49563/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Plasminogen Activator Inhibitor 1; 23583-48-4/8-Bromo Cyclic Adenosine Monophosphate; 65455-52-9/Percoll; 7631-86-9/Silicon Dioxide; 9001-31-4/Fibrin; 9003-39-8/Povidone; EC 3.4.21.73/Urokinase-Type Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Molecular cloning, functional expression and chromosomal localization of a human homolog of the cycl...
Next Document:  Quantitative evaluation of the dynamics of proton transfer from photoactivated bacteriorhodopsin to ...